Print this page
breast
-
A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/T-LBL).
Protocol: 112512Principal Investigator:
- Marissa Botwinick
Applicable Disease Sites: Lymphoid Leukemia -
The Women's Circle of Health Study.
Protocol: 130404Principal Investigator:
- Elisa V Bandera
Applicable Disease Sites: Breast - Female -
Adapting and Implementing Evidence-Based Breast Cancer Follow-up in Primary Care.
Protocol: 132103Principal Investigator:
- Shawna Hudson
Applicable Disease Sites: Breast -
Cancer Analytics and South Asian Health Breast Cancer Survivor Study (CANSAH-BC).
Protocol: 132204Applicable Disease Sites: Breast
-
Personalized Oncology Promoting Equity for Black Lives (PROPEL).
Protocol: 132309Principal Investigator:
- Anita Y Kinney
Applicable Disease Sites: Breast
Colon
Corpus Uteri
Ovary
Pancreas
Prostate -
ACCESS-PC: Advancing Care Coordination to Enhance Shared Care for Complex Survivors in Primary Care
Protocol: 132402Applicable Disease Sites: Breast
Corpus Uteri
Prostate
Urinary Bladder -
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors.
Protocol: 111702Principal Investigator:
- Nehal Parikh
Applicable Disease Sites: Any Site
Ovary
Prostate -
Translating Innovations in Cancer Screening into Substance Use Disorder
Care Settings (Just in Time)
Protocol: 132602Principal Investigator:
- Ana Tergas
Applicable Disease Sites: Cervix
Colon -
A Phase 2 Study of Inotuzumab Ozogamicin in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL).
Protocol: 111707Principal Investigator:
- Archana Sharma
Applicable Disease Sites: Lymphoid Leukemia -
A Phase 1 and Randomized Phase 2 Trial of Selinexor and Temozolomide in Recurrent Glioblastoma.
Protocol: 142301Principal Investigator:
- Vincent Yeung
Applicable Disease Sites: Brain and Nervous System -
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL).
Protocol: 111803Principal Investigator:
- Nehal Parikh
Applicable Disease Sites: Any Site -
Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) Versus Fractionated SRS (FSRS) for Intact Brain Metastases.
Protocol: 142403Applicable Disease Sites: Brain and Nervous System
-
Randomized Study of DOC1021 Dendritic Cell Immunotherapy in Combination with Standard of Care for Newly Diagnosed Adult Glioblastoma
Protocol: 142501Principal Investigator:
- Morana Vojnic
Applicable Disease Sites: Brain and Nervous System -
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL, Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy.
Protocol: 111911Principal Investigator:
- Marissa Botwinick
Applicable Disease Sites: Any Site -
A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations.
Protocol: 112008Principal Investigator:
- Marissa Botwinick
Applicable Disease Sites: Leukemia, not otherwise specified -
Palliative Dose Escalated Radiation for Painful Non-Spine Bone Metastases and Painful Non-Bone Metastases: A Phase II Study.
Protocol: 152201Principal Investigator:
- Matthew Deek
Applicable Disease Sites: Any Site